First, despite maximization of pharmacologically mediated therapeutic regimens which include ACE inhibitor therapy, patients with heart failure continue to develop pulmonary arterial hypertension via a reactive component, most likely mediated through pulmonary arterial endothelial dysfunction. This evidence concerns the gene ACE and heart failure.